Waugh, Norman, Royle, Pamela, Craigie, I., Ho, V., Pandit, L., Ewings, P., Adler, A. (Amanda), Helms, Peter, Prof. and Sheldon, C. (Christopher). (2012) Screening for cystic fibrosis-related diabetes : a systematic review. Health Technology Assessment, Vol.16 (No.24). ISSN 1366-5278

Preview	Text WRAP_Waugh_Screening_cystic_fibrosis.pdf - Published Version Download (1130Kb) | Preview
Preview	Text (Coversheet) WRAP_Waugh_Screening_cystic_fibrosis_coversheet.pdf - Supplemental Material Download (49Kb) | Preview

Abstract

Background Cystic fibrosis (CF) is an inherited disease that leads to damage to lungs, pancreas and other organs. Most people with CF die prematurely from lung disease, but survival has improved markedly over the decades and it is estimated that children born with CF now will live to an average age of 50 years. CF-related diabetes (CFRD) is due to damage to the pancreas, which, over time, loses its capacity to produce sufficient insulin. CFRD is becoming more common owing to the improved survival of people with CF. Objectives The initial aim was to review the methods for screening for CFRD, which can be symptomless but still be causing harm. As the aim of screening and early detection is to allow earlier treatment, a second aim was to assess the effectiveness of treatments. However, during the review it became clear that there were problems with how CFRD is defined, uncertainty about when hyperglycaemia should be treated. Data sources Details of relevant studies were obtained from the usual bibliometric databases – MEDLINE (1950–2008), EMBASE (1980–2008), The Cochrane Library (all sections), Web of Science (1970–2008). Websites of relevant bodies were searched for guidelines and reports. Conference abstracts were searched. Expert co-authors identified key papers. Review methods Systematic reviews of treatments and screening tests. Screening studies were data extracted if they provided sufficient data to construct 2 × 2 tables. Other screening studies were described in narrative manner. The background to CF and CFRD were described in a narrative manner, as was Chapter 2 on problems with defining CFRD. A model was constructed for cost-effectiveness analysis, but was not used because of lack of data. Results Diabetes is usually defined based on the level of blood glucose (BG) at which the risk of retinopathy occurs. For CFRD, it would be better to define it on the level at which the risk of lung disease (pulmonopathy) rises. There seems little place for treatments other than insulin, but the best insulin regimen remains to be confirmed. The best screening test may be by continuous glucose monitoring systems but further evidence is required. Screening may need to detect BG levels of > 8 mmol/l because that may be the level above which pulmonopathy starts in people with CF. Limitations The evidence base for treatment is disappointing with few large randomised controlled trials. The key question is when treatment should start, perhaps at the post-prandial hyperglycaemia stage. Research is needed. Until that is done, we cannot be sure what we are screening for, and, therefore, which screening strategy should be used. Conclusions The definition of CFRD should probably be based on pulmonopathy risk, rather than using the classical definition of diabetes. That implies that we should be screening for a wider range of hyperglycaemia than in other forms of diabetes, perhaps to detect BG excursions of > 8 mmol/l. Insulin treatment may need to start at lower levels than formerly accepted.

Item Type:	Journal Article
Subjects:	R Medicine > RC Internal medicine
Divisions:	Faculty of Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH):	Cystic fibrosis -- Complications, Diabetes -- Diagnosis, Diabetes -- Treatment
Series Name:	Health Technology Assessment
Journal or Publication Title:	Health Technology Assessment
Publisher:	NIHR Health Technology Assessment programme
ISSN:	1366-5278
Date:	May 2012
Volume:	Vol.16
Number:	No.24
Number of Pages:	179
Identification Number:	10.3310/hta16240
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
Funder:	NIHR Health Technology Assessment Programme (Great Britain)
References:	1. Brock DJ, Gilfillan A, Holloway S. The incidence of cystic fibrosis in Scotland calculated from heterozygote frequencies. Clinical Genetics 1998;53:47–9. 2. Dodge JA, Morison S, Lewis PA, Coles EC, Geddes D, Russell G et al. Incidence, population, and survival of cystic fibrosis in the UK, 1968–95. UK Cystic Fibrosis Survey Management Committee. Archives of Disease in Childhood 1997;77:493–6. 3. Assael BM, Castellani C, Ocampo MB, Iansa P, Callegaro A, Valsecchi MG. Epidemiology and survival analysis of cystic fibrosis in an area of intense neonatal screening over 30 years. American Journal of Epidemiology 2002;156:397–401. 4. Dodge JA, Lewis PA. Cystic fibrosis is no longer an important cause of childhood death in the UK. Archives of Disease in Childhood 2005;90:547. 5. Dodge JA, Lewis PA, Stanton M, Wilsher J. Cystic fibrosis mortality and survival in the UK: 1947–2003. European Respiratory Journal 2007;29:522–6. 6. Mackie AD, Thornton SJ, Edenborough FP. Cystic fibrosis-related diabetes. [Review] [145 refs]. Diabetic Medicine 2003;20:425–36. 7. Milla CE, Warwick WJ, Moran A. Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. American Journal of Respiratory & Critical Care Medicine 2000;162:t-5. 8. Yung B, Noormohamed FH, Kemp M, Hooper J, Lant AF, Hodson ME. Cystic fibrosis-related diabetes: the role of peripheral insulin resistance and beta-cell dysfunction. Diabetic Medicine 2002;19:221–6. 9. Couce M, O’Brien TD, Moran A, Roche PC, Butler PC. Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis. J Clin Endocrinol Metab 1996;81:1267–72. 10. Dobson L, Sheldon CD, Hattersley AT. Understanding cystic-fibrosis-related diabetes: best thought of as insulin deficiency?. [Review] [78 refs]. Journal of the Royal Society of Medicine 2004;97(Suppl.):35. 11. Brennan AL, Geddes DM, Gyi KM, Baker EH. Clinical importance of cystic fibrosis-related diabetes. [Review] [97 refs]. Journal of Cystic Fibrosis 2004;3:209–22. 12. Moran A, Phillips J, Milla C. Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care 2001;24:1706–10. 13. Andersen HU, Lanng S, Pressler T, Laugesen CS, Mathiesen ER. Cystic fibrosisrelated diabetes: the presence of microvascular diabetes complications. Diabetes Care 2006;29:2660–3. 14. Dobson L, Stride A, Bingham C, Elworthy S, Sheldon CD, Hattersley AT. Microalbuminuria as a screening tool in cystic fibrosis-related diabetes. Pediatric Pulmonology 2005;39:103–7. 15. Lanng S, Thorsteinsson B, Lund-Andersen C, Nerup J, Schiotz PO, Koch C. Diabetes mellitus in Danish cystic fibrosis patients: prevalence and late diabetic complications. Acta Paediatrica 1994;83:72–7. 16. Diabetes Prevention Program. The prevalence of retinopathy in impaired glucose tolerance and recent-onset diabetes in the Diabetes Prevention Program. Diabet Med 2007;24:137–44. 17. Drummond RS, Love A, Semple K, Bicknell S, Ross E, Small M et al. The favourable effect of insulin upon pulmonary function in patients with cystic fibrosis correlates with the degree of glucose intolerance at baseline. Diabetic Medicine 2006;23:43. 18. Brennan AL, Gyi KM, Wood DM, Johnson J, Holliman R, Baines DL et al. Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. Journal of Cystic Fibrosis 2007;6:101–9. 19. Rolon MA, Benali K, Munck A, Navarro J, Clement A, Tubiana-Rufi N et al. Cystic fibrosisrelated diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy. Acta Paediatrica 2001;90:860–7. 20. Allen HF, Gay EC, Klingensmith GJ, Hamman RF. Identification and treatment of cystic fibrosis-related diabetes. A survey of current medical practice in the US. [see comment]. Diabetes Care 1998;21:943–8. 21. Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003;163:1306–16. 22. Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T. Postprandial plasma glucose is an independent risk factor for increased carotid intima– media thickness in non-diabetic individuals. Atherosclerosis 1999;144:229–35. 23. von Drygalski A, Biller J. Anemia in cystic fibrosis (CF): Prevalence, mechanisms and correlation with pulmonary function. Blood (ASH Annual Meeting Abstracts) 2006;108:Poster Board Session 414–1. 24. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003;26:881–5. 25. Yung B, Kemp M, Hooper J, Hodson ME. Diagnosis of cystic fibrosis related diabetes: a selective approach in performing the oral glucose tolerance test based on a combination of clinical and biochemical criteria.[see comment]. Thorax 1999;54:40–3. 26. Australia and New Zealand Horizon Scanning Network. Continuous Glucose Monitoring Devices: Horizon Scanning Report. 2006 http://nzhta.chmeds.ac.nz/publications/finalcgmd. pdf (accessed 6 August 2007) 27. Mueller-Brandes C, Holl RW, Nastoll M, Ballmann M. New criteria for impaired fasting glucose and screening for diabetes in cystic fibrosis. European Respiratory Journal 2005;25:715–17. 28. UK Cystic Fibrosis Trust Diabetes Working Group. Management Of Cystic Fibrosis Related Diabetes Mellitus. 2004 http://www.cftrust.org.uk/aboutcf/publications/consensusdoc/ diabetes.pdf 29. Scottish Intercollegiate Guidelines Network. Management of Diabetes: SIGN Publication No. 55. 2001 http://www.sign.ac.uk/guidelines/fulltext/55/index.html 30. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Economic Evaluation Working Party. BMJ 1996;313:275–83. 31. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004;8:iii-xi, 1.
URI:	http://wrap.warwick.ac.uk/id/eprint/46293

Request changes to a record

Actions (login required)

View Item